Gefitinib for non-small-cell lung cancer treatment

Bibliography

• Jemal A, Siegel R, Ward E, Cancer Statistics, 2009. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A, FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Harbison CT, Hart LL, Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:918-27
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39
   PubMed Web of Science ®Google Scholar
• Ranson M, Hammond LA, Ferry D, ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a Phase I trial. J Clin Oncol 2002;20:2240-50
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Caputo R, Bianco R, Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:225-35
   Web of Science ®Google Scholar
• Yun CH, Mengwasser KE, Toms AV, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105:2070-5
   PubMed Web of Science ®Google Scholar
• Swaisland H, Laight A, Stafford L, Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 2001;40:297-306
   PubMed Web of Science ®Google Scholar
• Swaisland HC, Cantarini MV, Fuhr R, Exploring the relationship between expression of cytocrome P450 enzymes and gefitinib pharmacokinetics. Clin Pharmacokinet 2006;45:633-44
   PubMed Web of Science ®Google Scholar
• Swaisland HC, Ranson M, Smith RP, Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005;44:1076-81
   Web of Science ®Google Scholar
• Heimberger AB, Learn CA, Archer GE, Brain tumors in mice are susceptible to blockade of Epidermal Growth Factor Receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002;8:3496-502
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ardizzoni A, Soto-Parra H, Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer 2003;41:227-31
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Cappuzzo F, Gregorc V, Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004;15:1042-7
   PubMed Web of Science ®Google Scholar
• Hotta K, Kiura K, Ueoka H, Effect of gefitinib (‘Iressa’, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 2004;46:255-61
   PubMed Web of Science ®Google Scholar
• Namba Y, Kijima T, Yokota S, Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer 2004;6:123-8
   PubMedGoogle Scholar
• Fukuoka M, Yano S, Giaccone G, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS, Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer. A randomized trial. JAMA 2003;290:2149-58
   PubMed Web of Science ®Google Scholar
• Crino L, Cappuzzo F, Zatloukal P, Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE) a randomized, phase II study. J Clin Oncol 2008;26:4253-60
   PubMed Web of Science ®Google Scholar
• Goss G, Ferry D, Laurie S, Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 2009;27:2253-60
   PubMed Web of Science ®Google Scholar
• Cufer T, Vrdoljak E, Gaafar R, SIGN Study Group. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIB or IV) non-small-cell lung cancer. Anticancer Drugs 2006;17:401-9
   PubMed Web of Science ®Google Scholar
• Giaccone G, Herbst RS, Manegold C, Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1. J Clin Oncol 2004;22:777-84
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, Schiller JH, Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785-94
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsch V, Mok T, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet 2008;372:1809-18
   PubMed Web of Science ®Google Scholar
• Maruyama R, Nishiwaki Y, Tamura T, Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26:4244-52
   PubMed Web of Science ®Google Scholar
• Lee DH, Park K, Kim JH, Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010;16:1307-14
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Douillard J, Fukuoka M, Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials. J Clin Oncol 2009;27(Suppl):S15
   Google Scholar
• Thatcher N, Chang A, Parikh P, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11
   PubMed Web of Science ®Google Scholar
• Asahina H, Yamazaki K, Kinoshita I, A phase II trial of gefitinib as first-line therapy for advanced non small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006;95:998-1004
   PubMed Web of Science ®Google Scholar
• Inoue A, Suzuki T, Fukuhara T, Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-6
   PubMed Web of Science ®Google Scholar
• Sutani A, Nagai Y, Udagawa K, Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 2006;95:1483-9
   PubMed Web of Science ®Google Scholar
• Sunaga N, Tomizawa Y, Yanagitani N, Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 2007;56:383-9
   PubMed Web of Science ®Google Scholar
• Tamura K, Okamoto I, Kashii T, West Japan Thoracic Oncology Group. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 2008;98:907-14
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
   PubMed Web of Science ®Google Scholar
• Lee JS, Park K, Kim SW, A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol 2009;4(Suppl):PRS.4
   Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8
   PubMed Web of Science ®Google Scholar
• Frampton JE, Easthope SE. Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer. Drugs 2004;64:2475-92
   PubMed Web of Science ®Google Scholar
• Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer. Drug Saf 2004;27:1081-92
   PubMed Web of Science ®Google Scholar
• Takano T, Ohe Y, Kusumoto M, Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104
   PubMed Web of Science ®Google Scholar
• Ando M, Okamoto I, Yamamoto N, Predictive factors for interstitial lung Disease, antitumor response, and survival in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56
   PubMed Web of Science ®Google Scholar
• Yoshida S. The results of gefitinib prospective investigation. Med Drug J 2005;41:772-89
   Google Scholar
• Iressa: summary of product characteristics. European Medicines Agency. Avalaible from http://www.emea.europa.eu/humandocs/PDFs/EPAR/iressa/emea-combined-h-1016-en.pdf [Last accessed 7 August 2009]
   Google Scholar
• Inoue A, Kobayashi K, Usui K, North East Japan Gefitinib Study Group. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009;27:1394-400
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations. Ann Oncol 2010;21(Suppl):LBA13
   Google Scholar
• Rosell R, Gervais R, Vergnenegre A, Spanish Lung Cancer Group; Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol 2011;29(Suppl):7503
   Google Scholar
• Zhang L, Shenglin M, Song X, Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804). J Clin Oncol 2011;29(Suppl):LBA7511
   Google Scholar